ArticleGenes2022
miRNome Profiling Detects miR-101-3p and miR-142-5p as Putative Blood Biomarkers of Frailty Syndrome.
Article in Genes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07718958 (BIOMA-PANS - Diagnostic and Treatment-response BIOMArkers in Children and Adolescents With PANS), which is not on this map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
BIOMA-PANS - Diagnostic and Treatment-response BIOMArkers in Children and Adolescents With PANS (Pediatric Acute-onset Neuropsychiatric Syndrome)
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Challenges in Identifying Biomarkers of Frailty Syndrome: A Systematic Review.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Circulating miR-144-3p as a Novel Independent Biomarker Associated With Low Muscle Strength Among Older Adults.Journal of cachexia, sarcopenia and muscle · 2025Article
- The emerging role of miRNAs in biological aging and age-related diseases.Non-coding RNA research · 2025Review
- Engineering extracellular vesicles to transiently permeabilize the blood-brain barrier.Journal of nanobiotechnology · 2024Article
- Impact of microRNAs on cardiovascular diseases and aging.The Journal of international medical research · 2024Review
- Extracellular MicroRNAs as Potential Biomarkers for Frail Kidney Phenotype: Progresses and Precautions.Aging and disease · 2024Article
- Exploring miRNA Profiles in Colon Cancer: A Focus on miR101-3p, miR106a-5p, and miR326.Cancers · 2024Article
- Transcriptional repression of lncRNA and miRNA subsets mediated by LRF during erythropoiesis.Journal of molecular medicine (Berlin, Germany) · 2023Article
- Frailty Syndrome-Fall Risk and Rehabilitation Management Aided by Virtual Reality (VR) Technology Solutions: A Narrative Review of the Current Literature.International journal of environmental research and public health · 2022Review
- The regulatory network of potential transcription factors and MiRNAs of mitochondria-related genes for sarcopenia.Frontiers in genetics · 2022Article
- Functional role of miR-34a in diabetes and frailty.Frontiers in aging · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Frailty is an aging-related pathology, defined as a state of increased vulnerability to stressors, leading to a limited capacity to meet homeostatic demands. Extracellular microRNAs (miRNAs) were proposed as potential biomarkers of various disease conditions, including age-related pathologies. The primary objective of this study was to identify blood miRNAs that could serve as potential biomarkers and candidate mechanisms of frailty. Using the Fried index, we enrolled 22 robust and 19 frail subjects. Blood and urine samples were analysed for several biochemical parameters. We observed that sTNF-R was robustly upregulated in the frail group, indicating the presence of an inflammatory state. Further, by RNA-seq, we profiled 2654 mature miRNAs in the whole blood of the two groups. Expression levels of selected differentially expressed miRNAs were validated by qPCR, and target prediction analyses were performed for the dysregulated miRNAs. We identified 2 miRNAs able to significantly differentiate frail patients from robust subjects. Both miR-101-3p and miR-142-5p were found to be downregulated in the frail vs. robust group. Finally, using bioinformatics targets prediction tools, we explored the potential molecular mechanisms and cellular pathways regulated by the two miRNAs and potentially involved in frailty.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.